Technology
Patient-derived tumor models
Spanios utilizes a proprietary method to create patient-derived 3D tumor models that are stable, biobanked, and now disrupting how novel therapies are efficacy tested in the pre-clinical stage. We overcome limitations of traditional approaches such as xenografts and animal models by creating a resilient replica of host tumor environments. This keeps the focus on identifying new pathways, bringing optimal treatments to patients faster than ever before.
With Spanios’ technology, scientists and researchers benefit from a host of advantages over traditional approaches.
Time Efficient
Rapid efficacy testing
Fresh received: 2-3 weeks
Biobanked indications: 3-4 weeks
New indications: 4 months
Translatable Data
Transference rate is 200% higher than the industry standard
Reliability
Maintain genetic integrity & spatial fidelity of the original host tumor microenvironment
Reproducibility
Biobanked Tumoroids can be retrieved for confirmatory and follow on testing
More complex assays available click for more information
Advanced screening platform
Data is the foundation of research and the driver of innovation.
That’s why Spanios is investing in a sophisticated software platform that synthesizes structured data derived from our proprietary models and transforms it into actionable intelligence. Our approach provides researchers and clinicians with the confidence in knowing treatment recommendations and care decisions are backed by real lab data.